Generation Bio

Generation Bio EBIT/Assets

Delisted

The Operating Income to Assets Ratio (EBIT/Assets) of Generation Bio (GBIO) as of Nov 10, 2026 is -61.59 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -36.97 % — a change of 66.57% (lower).

EBIT/Assets

-61.59 %

YoY

66.57%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Generation Bio is 2024 -61.59 % . Operating Income to Assets Ratio (EBIT/Assets) of Generation Bio was 2023 -36.97 % . It decreases by 66.57% lower compared to the previous year.

The Generation Bio EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-44.65 USD
Jan 1, 2019
-147.85 USD
Jan 1, 2020
-27.58 USD
Jan 1, 2021
-24.98 USD
Jan 1, 2022
-37.52 USD
Jan 1, 2023
-36.97 USD
Jan 1, 2024
-61.59 USD
The Generation Bio EBIT/Assets history
YEAREBIT/AssetsYoY
-61.59 %+66.57%
-36.97 %-1.46%
-37.52 %+50.20%
-24.98 %-9.41%
-27.58 %-81.35%
-147.85 %+231.10%
-44.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Generation Bio Stock analysis

What does Generation Bio do? Generation Bio Co. is a genetic medicines company headquartered in Cambridge, Massachusetts, that focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The firm is developing a class of gene therapy utilizing its non-viral gene therapy platform to deliver genetic payloads to a range of tissues. The company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The firm is engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The firm is a preclinical stage company and have not identified a product candidate. Generation Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Generation Bio stock

Operating Income to Assets Ratio (EBIT/Assets) of Generation Bio is -61.59 % in 2024.

Operating Income to Assets Ratio (EBIT/Assets) of Generation Bio changed from -36.97 % to -61.59 %, representing a 66.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Generation Bio since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Generation Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Generation Bio

All Key Metrics — Generation Bio